Zacks Investment Research
09 Jul 2026, 16:40 UTC · 11w ago
Verdict
Headline takes no side. We score PRTA +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Roche expects its partnered drug with Prothena, prasinezumab, to have peak sales potential exceeding $3.5 billion.
So whatHigh potential peak sales for a late-stage Parkinson's drug provides a significant valuation catalyst for Prothena.
More positive than 93% of claims this week
Prothena received a $50 million clinical milestone payment in March related to phase III enrollment progress.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 79% of claims this week
Novo Nordisk is evaluating coramitug in the phase III CLEOPATTRA program for ATTR-CM, with completion expected by 2029.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 99% of ticker scores this week
Shares have gained 11% due to late-stage program advancement, milestone payments, and a solid cash position.
More positive than 77% of ticker scores this week
Evaluating prasinezumab with peak sales potential exceeding $3.5 billion and encouraging long-term clinical evidence.
More positive than 71% of ticker scores this week
Making meaningful late-stage progress with the phase III CLEOPATTRA program for ATTR amyloidosis.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1h ago
More positive than 75% of relationship scores this week
[mutual] Roche is a partner of Prothena evaluating prasinezumab in a late-stage study.
More positive than 56% of relationship scores this week
[a_to_b] Novo Nordisk acquired coramitug, which was initially developed by Prothena, in July 2021.
−11.5%
Price is moving against the score
$8.72 vs $9.85 close before publication (Jul 8) · not market-adjusted
PRTA chart →
